Acquisition and Disposition - The Company acquired 100% of Superlatus for a total fair value of $225,000,169, consisting of 136,441 shares of common stock and 306,855 shares of Series B Preferred Stock[20]. - The Company recognized a gain on the disposition of business amounting to $29,685,946, included in income from discontinued operations[24]. - As of March 31, 2024, the total carrying amount of assets and liabilities acquired in the Superlatus transaction was $2,083,743[21]. - The Company issued a promissory note to Perfect Day, Inc. for $4,400,000 as part of the acquisition consideration[35]. - The Company sold all equity shares of Superlatus Inc. for a nominal price of $1.00, resulting in the loss of $2,083,742 included in income from discontinued operations[50]. - The company completed the acquisition of Superlatus on July 31, 2023, with a merger consideration valued at $12,500,089[135]. - The merger consideration for Superlatus shareholders was adjusted to 136,441 shares of common stock and 15,759 shares of Series B Preferred Stock, valued at $12,500,089 at the time of closing[200]. Financial Performance - Total product revenue for the three months ended March 31, 2024, was $476,356, with total service revenue of $16,960, resulting in total revenue of $493,316[53]. - Total revenues for Q1 2024 were $0, down from $493,316 in Q1 2023, representing a 100% decrease[122]. - Operating expenses surged to $5,496,471 in Q1 2024, a 525% increase from $879,309 in Q1 2023, driven by a 1902% increase in general and administrative expenses[122]. - Net loss from operations for Q1 2024 was $(6,636,922), compared to $(1,136,637) in Q1 2023, marking a 484% increase in losses[122]. - Net income from discontinued operations rose to $27,882,955 in Q1 2024, up from $458,684 in Q1 2023, reflecting a 5979% increase due to the disposal of Trxade, Inc.[125]. - The company reported no revenues for Q1 2024, a decrease of $493,316 compared to the same period in 2023[169]. - The company reported a net income of $21,246,033 for March 2024, contrasting with a net loss of $677,953 in the same period last year[215]. Cash Flow and Liquidity - Cash used in operations for Q1 2024 was $(10,189,673), a significant increase from $(931,531) in Q1 2023, primarily due to shares issued for services valued at $4,450,919 and increased expenses[121]. - Cash balance as of March 31, 2024, was $3,498,812, a dramatic increase of 968108% from $361 on December 31, 2023[139]. - Cash provided by investing activities for Q1 2024 was $27,432,589, a substantial increase from $333,197 in Q1 2023, primarily due to the disposition of Trxade, Inc. and Superlatus, Inc.[167]. - Cash used in financing activities for Q1 2024 was $(13,896,011), a decrease from cash provided of $681,257 in Q1 2023, largely due to repayment of contingent funding liability and dividend payments[144]. - The company declared a special cash dividend of $8.00 per share, totaling $12,671,072, to be paid on March 22, 2024, funded by proceeds from the sale of Trxade assets[118]. Expenses and Liabilities - General and administrative expenses rose to $4,700,840 in Q1 2024, compared to $248,021 in Q1 2023, mainly due to stock-based compensation[147]. - The company recorded total lease expenses of $20,925 for the three months ended March 31, 2024, compared to $81,024 for the same period in 2023[103]. - Current liabilities decreased by 74% to $2,951,387 as of March 31, 2024, down from $11,556,355 on December 31, 2023[139]. - The company has substantial doubt about its ability to continue as a going concern due to the need for additional capital, which may not be available on favorable terms[196]. Stock and Shareholder Information - The company issued 470,482 shares of common stock for services, with a fair value of $4,450,919 included in general and administrative expenses[40]. - The weighted average common shares outstanding increased to 1,036,756 from 670,716 year-over-year, reflecting potential dilution[215]. - The company has not repurchased any shares of common stock during the first quarter of 2024[192]. Internal Controls and Compliance - The company does not expect its disclosure controls and procedures to prevent or detect all errors and fraud, indicating a need for ongoing evaluation and improvement[155]. - The company has not fully implemented necessary internal controls, leading to material weaknesses in financial reporting processes[180]. - The company is currently not in compliance with Nasdaq's continued listing standards, which may affect its ability to maintain its listing on the Nasdaq Capital Market[198]. Future Outlook and Strategy - The company anticipates its future capital resources will primarily consist of cash generated from operations, remaining cash balances, borrowings, and additional funds raised through sales of debt and/or equity securities[115]. - The company plans to continue operational expansions on its Trxade Prime platforms and explore strategic transactions for its business-to-consumer subsidiaries[140]. - The company plans to continue using existing marketing and management strategies while exploring strategic transactions and potential acquisitions[165]. - The company may need to raise additional capital or secure debt funding to support ongoing operations, which could lead to significant dilution for existing stockholders[187].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _____________to______________ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | | --- | --- | | (State or other jurisdiction of | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | | --- ...

TRxADE HEALTH, Inc. (NASDAQ:MEDS) Q1 2023 Earnings Conference Call May 15, 2023 6:00 PM ET Company Participants Prashant Patel - Interim Chief Financial Officer Suren Ajjarapu - Founder, Chairman and Chief Executive Officer Conference Call Participants Allen Klee - Maxim Group LLC Howard Halpern - Taglich Brothers, LLC Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to TRxADE HEALTH's Quarter One 2023 Earnings Conference Call. During today's presentation, all parties will b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 46-3673928 (State or ...

TRxADE HEALTH, Inc. (NASDAQ:MEDS) Q4 2022 Earnings Conference Call March 27, 2023 5:30 PM ET Company Participants Prashant Patel - CFO Surendra Ajjarapu - Founder, Chairman and CEO Conference Call Participants Allen Klee - Maxim Group Howard Halpern - Taglich Brothers Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to TRxADE HEALTH's 2022 Annual Earnings Conference Call. [Operator Instructions] The earnings press release accompanying this conference call was issued at the c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: _____________to______________ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 ...

TRxADE Health, Inc. (NASDAQ:MEDS) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Janet Huffman - CFO & Principal Accounting Officer Surendra Ajjarapu - Founder, Chairman, CEO, Treasurer & Secretary Conference Call Participants Allen Klee - Maxim Group Howard Halpern - Taglich Brothers Operator Good afternoon, and welcome to TRxADE Conference Call. [Operator Instructions]. Today with us, we have Suren Ajjarapu, Howard Dossand and Janet Huffman. I would now like to turn the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission File Number: 001-39199 TRxADE HEALTH, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-3673928 | ...